Oxaliplatin - PharmaKB

Oxaliplatin

Oxaliplatin (oxaliplatin) is a small molecule pharmaceutical. Oxaliplatin was first approved as Eloxatin on 2002-08-09. It is used to treat colorectal neoplasms, ovarian neoplasms, testicular neoplasms, and urinary bladder neoplasms in the USA.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
neoplasms	D009369
digestive system diseases	D004066
urogenital diseases	D000091642
endocrine system diseases	D004700

Trade Name

FDA

EMA

Oxaliplatin (discontinued: Eloxatin, Oxaliplatin)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Oxaliplatin

Tradename	Company	Number	Date	Products
OXALIPLATIN	Teva	N-022160 RX	2009-08-07	2 products, RLD, RS

Show 2 discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
oxaliplatin	New Drug Application	2024-10-28

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
colorectal neoplasms	—	D015179	—
ovarian neoplasms	EFO_0003893	D010051	C56
urinary bladder neoplasms	—	D001749	C67
testicular neoplasms	—	D013736	C62

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

L: Antineoplastic and immunomodulating agents

— L01: Antineoplastic agents

— L01X: Other antineoplastic agents in atc

— L01XA: Platinum compounds, antineoplastic drugs

— L01XA03: Oxaliplatin

HCPCS

Code	Description
J9263	Injection, oxaliplatin, 0.5 mg

Clinical

Clinical Trials

2844 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Colorectal neoplasms	D015179	—	—	151	490	185	19	85	833
Stomach neoplasms	D013274	EFO_0003897	C16	63	318	104	4	48	481
Adenocarcinoma	D000230	—	—	86	292	80	2	21	431
Pancreatic neoplasms	D010190	EFO_0003860	C25	91	199	41	2	22	311
Rectal neoplasms	D012004	—	—	38	201	58	1	32	305
Neoplasms	D009369	—	C80	126	123	43	4	15	275
Carcinoma	D002277	—	C80.0	42	151	65	1	28	263
Liver neoplasms	D008113	EFO_1001513	C22.0	18	116	54	11	29	209
Neoplasm metastasis	D009362	EFO_0009708	—	29	115	38	13	21	193
Esophageal neoplasms	D004938	—	C15	33	120	20	1	12	164

Show 14 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Recurrence	D012008	—	—	11	36	13	—	3	61
Biliary tract neoplasms	D001661	—	C24.9	11	52	5	—	2	61
Peritoneal neoplasms	D010534	—	—	15	22	10	—	7	50
Large b-cell lymphoma diffuse	D016403	—	C83.3	15	27	10	—	1	45
B-cell lymphoma	D016393	—	—	12	25	10	—	1	39
Non-small-cell lung carcinoma	D002289	—	—	21	21	1	—	—	37
Gallbladder neoplasms	D005706	EFO_0004606	C23	10	26	5	—	2	36
Ovarian neoplasms	D010051	EFO_0003893	C56	15	17	1	—	2	30
Neoadjuvant therapy	D020360	—	—	1	15	5	—	8	28
Lung neoplasms	D008175	HP_0100526	C34.90	8	19	1	—	1	26

Show 57 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Breast neoplasms	D001943	EFO_0003869	C50	12	18	—	—	7	36
Immunotherapy	D007167	—	—	2	15	—	—	4	19
Head and neck neoplasms	D006258	—	—	2	14	—	—	1	16
Intestinal neoplasms	D007414	—	C26.0	4	8	—	—	2	13
Appendiceal neoplasms	D001063	EFO_0003880	C18.1	6	4	—	—	2	12
Triple negative breast neoplasms	D064726	—	—	7	6	—	—	1	11
Squamous cell carcinoma of head and neck	D000077195	—	—	6	5	—	—	—	10
Gastrointestinal diseases	D005767	—	—	2	8	—	—	—	9
Leukemia	D007938	—	C95	5	5	—	—	—	7
Mesothelioma	D008654	—	C45	2	2	—	—	3	7

Show 128 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hematologic neoplasms	D019337	—	—	2	—	—	—	—	2
Lymphoid leukemia	D007945	—	C91	2	—	—	—	—	2
Diarrhea	D003967	HP_0002014	R19.7	1	—	—	—	1	2
Skin neoplasms	D012878	EFO_0004198	C44	2	—	—	—	—	2
T-cell lymphoma cutaneous	D016410	—	—	2	—	—	—	—	2
Lymphomatoid granulomatosis	D008230	—	C83.8	2	—	—	—	—	2
Pleural effusion	D010996	HP_0002202	J90	1	—	—	—	1	2
Pleural neoplasms	D010997	—	—	1	—	—	—	1	2
Myeloproliferative disorders	D009196	—	D47.1	1	—	—	—	—	1
Primary myelofibrosis	D055728	—	D47.4	1	—	—	—	—	1

Show 29 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Esophageal and gastric varices	D004932	EFO_0009545	I85	—	—	—	—	4	4
Hypertension	D006973	EFO_0000537	I10	—	—	—	—	3	3
Prognosis	D011379	—	—	—	—	—	—	2	2
Hemorrhage	D006470	MP_0001914	R58	—	—	—	—	2	2
Portal hypertension	D006975	EFO_0000666	K76.6	—	—	—	—	2	2
Body weight	D001835	EFO_0004338	—	—	—	—	—	1	1
Weight loss	D015431	HP_0001824	—	—	—	—	—	1	1
Fatigue	D005221	HP_0012378	R53.83	—	—	—	—	1	1
Fatal outcome	D017809	—	—	—	—	—	—	1	1
Stents	D015607	—	—	—	—	—	—	1	1

Show 16 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Oxaliplatin
INN	oxaliplatin
Description	Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication (platinum-based antineoplastic class) used to treat colorectal cancer. It is given by injection into a vein.
Classification	Small molecule
Drug class	antineoplastics (platinum derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	—